| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.0M | — |
| R&D Expense | $118.0M | +14.1% |
| SG&A Expense | $28.7M | -0.6% |
| Operating Income | -$139.7M | -5.6% |
| Net Income | -$127.2M | -4.4% |
| EPS (Basic) | -$1.68 | +16.8% |
| EPS (Diluted) | -$1.68 | +16.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $12.5M | -50.7% |
| Short-term Investments | $121.1M | -41.7% |
| Current Assets | $135.9M | -42.3% |
| Total Assets | $175.5M | -36.8% |
| Current Liabilities | $25.6M | +17.5% |
| Total Liabilities | $44.1M | +8.6% |
| Stockholders' Equity | $131.5M | -44.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$102.9M | +3.9% |
| Capital Expenditures | $764K | -78.3% |
| Investing Cash Flow | $90.2M | +360.3% |
| Financing Cash Flow | -$120K | -100.1% |
| Free Cash Flow | -$103.7M | +6.3% |